Kopran is an integrated Indian pharmaceutical maker that has spent over six decades building a bridge from bulk drug chemistry to finished pills, all aimed at export markets. It was founded in 1958 and now operates through two tightly linked verticals-Active Pharmaceutical Ingredients (APIs) made by its subsidiary Kopran Research Laboratories, and finished-dosage formulations made directly by Kopran Limited-with a recurring approach of chasing high-value, technologically difficult molecules and then using its own APIs inside its own tablets to control cost and quality. A proposed merger with a promoter-group diagnostics company signals the same pattern again: use existing manufacturing muscle to enter a new healthcare segment. # Business segments Two engines that feed each other-an API powerhouse that supplies the world’s drug factories and a formulations business that turns those same molecules into finished medicines for export-with a diagnostics platform being stitched on. ## 1. Active Pharmaceutical Ingredients: the chemistry engine that drives the group **Kopran is the world’s second-largest maker of Atenolol and one of the few manufacturers globally with a full basket of sterile carbapenem antibiotics, which together anchor a portfolio of over two dozen high-value APIs.** - **Regulatory approvals are the entry ticket** - the API plant at Mahad holds approvals from ANVISA (Brazil), US FDA, EU GMP, WHO GMP, COFEPRIS (Mexico), and KFDA (South Korea), which means its molecules can be sold into most regulated markets. Seven US Drug Master Files are already filed for products including Atenolol, Pregabalin, and Azithromycin, and Atenolol is approved by the US FDA, European authorities, and China’s SFDA. - **A second plant for the next wave** - a new API facility at Panoli, Gujarat, is being built to manufacture newer molecules like the blood thinners Ticagrelor, Apixaban, and Rivaroxaban, and has received environmental clearance to produce up to 97 metric tonnes per month of synthetic organic chemicals. This expands capacity beyond the existing Mahad site, which already houses dedicated plants for Atenolol, sterile carbapenems, macrolides, and cephalosporins. - **Fighting Chinese competition with chemistry** - the company faces price pressure on Penems from Chinese rivals, so it deliberately develops synthesis-based key starting materials rather than fermentation-based ones, a process choice that insulates it from the cost advantages of Chinese fermentation at scale. It also develops its own intermediates for APIs to reduce import dependency. - **A pipeline built on patent expiries** - Kopran has already commercialised cardiac products like Ticagrelor, Rivaroxaban, and Apixaban for the domestic market and is awaiting international regulatory approvals as patents expire, while products like Edoxaban (a blood thinner) and its intermediates have had their process developed and are being manufactured. ## 2. Formulations: the finished-medicine arm that captures the full value chain **A 100% export-focused factory that makes over 100 dosage forms-tablets, capsules, dry syrups, and soon injectables-and sells them either as contract-manufactured goods for regulated markets or as branded generics through distributors in Africa and Asia.** - **Two separate production lines under one roof** - the Khopoli facility has dedicated manufacturing lines for penicillin-based drugs (1,500 million capsules, 500 million tablets, and 20 million bottles of dry syrup annually) and non-penicillin drugs (2,000 million uncoated tablets, 1,000 million coated tablets, and 500 million capsules annually), preventing cross-contamination and meeting international regulatory expectations. - **Accreditations from 15 countries unlock the door** - the plant holds approvals from MHRA (UK), Health Canada, SAPHRA (South Africa), EU GMP via Malta, and multiple regulators across Africa, the Middle East, and Southeast Asia, which is why it can serve both tightly regulated and emerging markets from a single site. More than 549 product approvals have been secured across 46 countries. - **Two different go-to-market models** - in regulated markets like Canada and the UK, Kopran acts as a contract manufacturer (CMO) for other pharma companies, while in rest-of-world markets it markets directly through local distributors, with branded generics making up about 20-25% of formulation exports. It also participates in large government tenders in Africa, having executed sizeable contracts in the SADC region, Tanzania, and Ethiopia. - **Its own APIs are the cost advantage** - because the formulations business can source several APIs from the group’s own Mahad plant, it gets built-in cost efficiency and quality control that independent formulation players lack, particularly for penicillin-based and macrolide antibiotics. This integration is the structural reason the two verticals are more valuable together. - **Injectables are the next leg** - a vial-filling line for injectable products is being installed, expected to take 1 to 1.5 years to complete, after which product registrations will begin, adding a new dosage form to the existing oral-solids and dry-powder range. # Group structure and partners **A parent company with a wholly owned API subsidiary, two dormant offshore entities, and a promoter-group diagnostics business being folded in through a merger that will raise promoter ownership above 55%.** - **The API engine sits in a subsidiary** - Kopran Research Laboratories Ltd. (KRLL) runs the entire API business, with Kopran Limited holding 99.50%. Kopran Limited infused Rs.100 Crore into KRLL via a rights issue in March 2022, and KRLL’s board approved a further Rs.18.75 Crore rights issue in May 2026 for working capital. - **Two dormant subsidiaries exist** - Kopran (H.K.) Ltd. in Hong Kong and Kopran Lifesciences Ltd. are both wholly owned but had no turnover in FY 2020-21. - **A diagnostics merger is underway** - a Scheme of Amalgamation will absorb Kopran Laboratories Limited (a promoter-group company that markets diagnostic equipment, consumables, and automation solutions to pathlabs and hospitals across India) into Kopran Limited, with an appointed date of January 1, 2025. The merger lets Kopran enter the Indian diagnostics industry and use its manufacturing capabilities to repack and produce diagnostic kits, while increasing promoter shareholding from 44.46% to 55.36%. Shareholders approved the scheme on June 3, 2026, with 99.96% votes in favour. - **A family settlement has simplified control** - in September 2025, the promoters executed a Memorandum of Family Settlement that consolidated management and control of Kopran Ltd solely with one family branch, resolving long-standing disputes among three promoter groups.